Singapore’s VisVires Backs Israeli Shrimp-Health Startup ViAqua
ViAqua’s first product prevents and treats several ailments in shrimp, including white spot syndrome virus
Founded in 2014 and based in the Galilee, ViAqua develops a particle-based method for orally administering antiviral medication to shrimp. ViAqua’s first product, expected to go on the market in the next few months, prevents and treats several ailments including white spot syndrome virus, a highly contagious and deadly virus. Previous investors in ViAqua include Dutch animal feed company Nutreco NV, Singapore-listed, Israel-based venture firm Trendlines Group Ltd., and Israeli research university Technion Israel Institute of Technology.